<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776373</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 25406</org_study_id>
    <nct_id>NCT00776373</nct_id>
  </id_info>
  <brief_title>Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies</brief_title>
  <acronym>UPCC 25406</acronym>
  <official_title>A Phase I/II, Open-label Single Institution Study Evaluating Rapamycin in Combination With High-dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety, tolerability and efficacy of rapamycin in combination with HiVAC in
      relapsed and refractory patients with aggressive lymphoid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability and efficacy of rapamycin in combination with HiVAC in relapsed and refractory patients with aggressive lymphoid malignancies</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess and quantify phosphorylation of p70S6 kinase</measure>
    <time_frame>Study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether increased mTOR pathway inhibition correlates with response to therapy with rapamycin and HiVAC</measure>
    <time_frame>Study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>ALL</condition>
  <condition>Burkitt's Lymphoma</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <condition>CML</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin + high dose etoposide and cytarabine</intervention_name>
    <description>Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced lymphoid leukemia (primary refractory ALL; Relapsed ALL; CML in lymphoid
             accelerated phase or blast crisis; relapsed or refractory Burkitt's lymphoma; relapsed
             or refractory T-cell adult leukemia/lymphoma; relapsed or refractory lymphoblastic
             lymphoma

          -  &gt;= 18 and &lt;= 65 years of age ECOG performance status 0, 1 Life expectancy &gt;= 4 weeks
             Able to consume oral medication Required initial laboratory values: Creatinine &lt;=
             2.0mg/dL, total or direct bilirubin &lt;= 1.5 mg/dL, SGPT(ALT) &lt;=ULN, glucose &lt; 200
             mg/dL, negative pregnancy test for women with child bearing potential

        Exclusion Criteria:

          -  Subjects must not be receiving any chemotherapy agents (except Hydroxyurea)

          -  Subjects must not have received high-dose Ara-C within 6 months of relapse

          -  Subjects must not be receiving growth factors, except for erythropoietin

          -  No currently active second malignancy other than non-melanoma skin cancers

          -  No subjects with uncontrolled high blood pressure, unstable angina, symptomatic
             congestive heart failure, MI within the last 6 months or serious uncontrolled cardiac
             arrhythmia

          -  Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort,
             Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil,
             Tacrolimus

          -  Known HIV positivity or AIDS-related illness

          -  Evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with
             Ara-C administration

          -  Pregnant or lactating

          -  Uncontrolled infection

          -  Taking fluconazole, voriconazole, itraconazole and ketoconazole currently or within
             one week of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selina Luger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Abramson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>Burkitt's Lymphoma</keyword>
  <keyword>Adult T-Cell leukemia/lymphoma</keyword>
  <keyword>Lymphoblastic leukemia</keyword>
  <keyword>CML in lymphoid blast crisis patients</keyword>
  <keyword>HiVAC</keyword>
  <keyword>Rapamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

